St. Jude Medical and its investors have weathered quite a storm in the medical device industry. The company has pushed past falling sales and earnings through 2013 to post remarkable gains over the past 52 weeks. Still, growth has remained elusive in some of St. Jude's top business divisions. The company has turned to one of its smaller businesses with big potential for its future: neuromodulation.
St. Jude's neuromodulation business made up less than 10% of its total sales through the nine months of 2013 that ended in September, but this division's managed to eke out minor growth despite slips at St. Jude's larger units. The company's banking on a new trial of its Prodigy next-generation neurostimulation device to help boost growth in the near future, launching a new study of the device in the U.S. this week.
But can the Prodigy device -- and St. Jude's neuromodulation business -- help restore growth to this cardiovascular giant? Fool contributor Dan Carroll tells you all you need to know in the video below, and explains how tough competition from the likes of Medtronic and Stryker will weigh on St. Jude's neuromodulation push.
The growth opportunity that could light the market on fire
St. Jude has been a big winner this year for investors despite its financial slump, but there's one incredible stock that's not only beating St. Jude's gains, but boasts of a potential that every investor needs to know. This tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!
The article Can This Cardiac King Find Its Nerve? originally appeared on Fool.com.Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.